Search research articles
Contact Us
Filters
Showing results (61-70 of 115) with videos related to
Page
of 12
Sort By:
Cell Reports
|
April 9, 2013
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence
Katherine M Aird, Gao Zhang, Hua Li, et al.
Cancer Gene Therapy
|
November 29, 2023
CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR
Jaidev Bapat, Tomomi M Yamamoto, Elizabeth R Woodruff, et al.
Molecular Cancer Therapeutics
|
April 4, 2022
Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
Tomomi M Yamamoto, Patricia G Webb, Dana M Davis, et al.
Oncogenesis
|
November 28, 2018
CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer
Lindsay J Wheeler, Zachary L Watson, Lubna Qamar, et al.
Cancer Research
|
August 6, 2011
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence
Benjamin G Bitler, Jasmine P Nicodemus, Hua Li, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2024
Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents
Fabian R Villagomez, Julie Lang, Daniel Nunez-Avellaneda, et al.
The Journal of Biological Chemistry
|
November 20, 2019
Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine <i>O-</i>acyltransferase or Wnt secretion
Deviyani M Rao, Madeleine T Shackleford, Evelyn K Bordeaux, et al.
Cancer Research Communications
|
December 3, 2024
Claudin-4 Stabilizes the Genome via Nuclear and Cell-Cycle Remodeling to Support Ovarian Cancer Cell Survival
Fabian R Villagomez, Julie Lang, Daniel Nunez-Avellaneda, et al.
Cell Reports
|
December 21, 2017
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, et al.
Gynecologic Oncology
|
May 25, 2025
The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective
Eseohi Ehimiaghe, Nicole Marjon, Miriam D Post, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 115) with videos related to
Sort By:
Page
of 12
Cell Reports
|
April 9, 2013
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence
Katherine M Aird, Gao Zhang, Hua Li, et al.
Cancer Gene Therapy
|
November 29, 2023
CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR
Jaidev Bapat, Tomomi M Yamamoto, Elizabeth R Woodruff, et al.
Molecular Cancer Therapeutics
|
April 4, 2022
Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
Tomomi M Yamamoto, Patricia G Webb, Dana M Davis, et al.
Oncogenesis
|
November 28, 2018
CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer
Lindsay J Wheeler, Zachary L Watson, Lubna Qamar, et al.
Cancer Research
|
August 6, 2011
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence
Benjamin G Bitler, Jasmine P Nicodemus, Hua Li, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2024
Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents
Fabian R Villagomez, Julie Lang, Daniel Nunez-Avellaneda, et al.
The Journal of Biological Chemistry
|
November 20, 2019
Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine <i>O-</i>acyltransferase or Wnt secretion
Deviyani M Rao, Madeleine T Shackleford, Evelyn K Bordeaux, et al.
Cancer Research Communications
|
December 3, 2024
Claudin-4 Stabilizes the Genome via Nuclear and Cell-Cycle Remodeling to Support Ovarian Cancer Cell Survival
Fabian R Villagomez, Julie Lang, Daniel Nunez-Avellaneda, et al.
Cell Reports
|
December 21, 2017
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, et al.
Gynecologic Oncology
|
May 25, 2025
The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective
Eseohi Ehimiaghe, Nicole Marjon, Miriam D Post, et al.
Page
of 12